newsfilter
← Latest News
GlobeNewswire·

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024

LISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, announced positive clinical data from its UB-312 program in